[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Letters
July 5, 2006

Treatment of Antiphospholipid Antibody Syndrome—Reply

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2006;296(1):42-43. doi:10.1001/jama.296.1.43-a

In Reply: We agree with Drs Wahl and Regnault that outcome data from patients with a single positive antiphospholipid antibody test may not be generalizable to patients with definite APS, as defined by the Sapporo criteria1 or more recently proposed amendments to these criteria.2 We address this issue in our review and qualify our recommendations for the use of aspirin or warfarin in the treatment of stroke to indicate that they apply to “patients with a first ischemic stroke and a single positive antiphospholipid antibody test result . . . ,” reflecting the design of the Antiphospholipid Antibodies and Stroke Study.3 No randomized trials have evaluated different antithrombotic treatments in patients with stroke in whom APS was diagnosed according to the Sapporo criteria.

First Page Preview View Large
First page PDF preview
First page PDF preview
×